UnityPoint Health has launched a corporate venturing arm, UnityPoint Health Ventures Innovation Fund, that will invest in areas such as digital health and medical devices.

GlaxoSmithKline, Novartis and Astellas are among the investors to have celebrated an exit after cancer therapy developer Bicycle secured $60.7m in its initial public offering.

UCB Ventures and Alphabet unit GV took part in the RNA-targeting gene therapy developer's first publicly disclosed funding round, which was led by Arch Venture Partners.

GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer.

Merck & Co and Lilly Asia Ventures will exit the biotherapeutics technology developer in an acquisition by Evotec that will be sized at up to $90m.

Eli Lilly, WuXi Biologics and Alexandria-backed cancer and orphan disease therapy developer Inhibrx has received $40m in funding from Viking Global Investors.

MassMutual Ventures co-led the healthcare data platform developer's series B round, which also featured Aviva Ventures and Jianke.

William Taranto spoke about his near decade at Merck Global Health Innovation Fund and how corporate venturing has evolved in that time.

Medtronic, LivaNova and Baxter Healthcare have helped commit $53.5m for the third medical device-based fund to be raised under the MD Start moniker.

Alphabet, Novartis and Johnson & Johnson have contributed to a series C round for Cala Health, which is preparing to release its wearable hand-tremor treatment device.